Rapid approval of generic biopharmaceuticals eyed

Published: 2007-09-06 07:00:00

Updated: 2007-09-06 07:00:00

The Korea Food and Drug Administration is moving to establish a new regulation to allow the speedy product license procedures of generic biodrugs for the domestic pharmaceutical industry that is expected to be hard hit by the trade pact with the United States.

The support measures for the phar...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK